Accesso pubblico

Articoli con mandati relativi all'accesso pubblico - Douglas G AltmanUlteriori informazioni

Non disponibili pubblicamente: 31

Controlla

Analysing data and undertaking meta‐analyses

JJ Deeks, JPT Higgins, DG Altman, Cochrane Statistical Methods Group

Cochrane handbook for systematic reviews of interventions, 241-284, 2019

Mandati: National Institute for Health Research, UK

Controlla

Development and validation of a prediction model with missing predictor data: a practical approach

Y Vergouwe, P Royston, KGM Moons, DG Altman

Journal of clinical epidemiology 63 (2), 205-214, 2010

Mandati: Cancer Research UK

Controlla

Ten steps towards improving prognosis research

H Hemingway, RD Riley, DG Altman

Bmj 339, 2009

Mandati: US National Institutes of Health

Controlla

Visualizing and assessing discrimination in the logistic regression model

P Royston, DG Altman

Statistics in medicine 29 (24), 2508-2520, 2010

Mandati: Cancer Research UK

Controlla

Microvessel density as a prognostic factor in non-small-cell lung carcinoma: a meta-analysis of individual patient data

M Trivella, F Pezzella, U Pastorino, AL Harris, DG Altman

The lancet oncology 8 (6), 488-499, 2007

Mandati: Cancer Research UK

Controlla

The EQUATOR Network and reporting guidelines: Helping to achieve high standards in reporting health research studies

I Simera, D Moher, J Hoey, KF Schulz, DG Altman

Maturitas 63 (1), 4-6, 2009

Mandati: Cancer Research UK

Controlla

Reviews assessing the quality or the reporting of randomized controlled trials are increasing over time but raised questions about how quality is assessed

A Dechartres, P Charles, S Hopewell, P Ravaud, DG Altman

Journal of clinical epidemiology 64 (2), 136-144, 2011

Mandati: Cancer Research UK

Controlla

Pragmatic trials can be designed as optimal medical care: principles and methods of care trials

J Raymond, TE Darsaut, DG Altman

Journal of clinical epidemiology 67 (10), 1150-1156, 2014

Mandati: Cancer Research UK

Controlla

Writing a research article that is “fit for purpose”: EQUATOR Network and reporting guidelines

I Simera, DG Altman

BMJ Evidence-Based Medicine 14 (5), 132-134, 2009

Mandati: Canadian Institutes of Health Research, Cancer Research UK

Controlla

Standard 5: selection, measurement, and reporting of outcomes in clinical trials in children

IP Sinha, DG Altman, MW Beresford, M Boers, M Clarke, J Craig, ...

Pediatrics 129 (Supplement_3), S146-S152, 2012

Mandati: Cancer Research UK

Controlla

Tracking eye gaze during interpretation of endoluminal three-dimensional CT colonography: visual perception of experienced and inexperienced readers

S Mallett, P Phillips, TR Fanshawe, E Helbren, D Boone, A Gale, ...

Radiology 273 (3), 783-792, 2014

Mandati: Cancer Research UK, National Institute for Health Research, UK

Controlla

NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus

JL Chen, A Dawoodji, A Tarlton, S Gnjatic, A Tajar, I Karydis, J Browning, ...

International journal of cancer 136 (6), E590-E601, 2015

Mandati: Cancer Research UK, UK Medical Research Council

Controlla

Peer reviewers identified spin in manuscripts of nonrandomized studies assessing therapeutic interventions, but their impact on spin in abstract conclusions was limited

C Lazarus, R Haneef, P Ravaud, S Hopewell, DG Altman, I Boutron

Journal of clinical epidemiology 77, 44-51, 2016

Mandati: National Institute for Health Research, UK

Controlla

The time has come to register diagnostic and prognostic research

DG Altman

Clinical chemistry 60 (4), 580-582, 2014

Mandati: Cancer Research UK

Controlla

Statistical considerations for the development of prescriptive fetal and newborn growth standards in the INTERGROWTH‐21^st Project

DG Altman, EO Ohuma, ...

BJOG: An International Journal of Obstetrics & Gynaecology 120, 71-76, 2013